Top 10 Pharma Drug Discovery and Delivery Capital Raises in the U.S. – May 1st to 15th, 2025
Several interesting transactions closed in the Pharma Drug Discovery and Delivery sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
- MAIA Biotechnology Inc, a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, received $1.08 million of development capital from Mr. Stan Smith, Mr. Ramiro Guerrero and other investors on May 8, 2025.
- MetaVia Inc., a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases, received $10 million of development capital from investors on May 12, 2025.
Merger/Acquisition
- 2Seventy Bio, a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, was acquired by Bristol-Myers Squibb for $501.03 million on May 13, 2025.
- Strata Biotech Labs, operator of an FDA-certified facility registered with the Department of Defense, producing capsules, tablets, skincare, and animal wellness products, was acquired by TRB Holdings on May 8, 2025.
Later Stage VC
- Granata Bio, operator of a biopharma company intended to find and grow fertility programs for patients, raised venture funding from Chemical Works of Gedeon Richter on May 14, 2025.
- PAQ Therapeutics, operator of a biotechnology company intended to restore health and cure disease through autophagy, raised $39 million of venture funding in a deal led by MRL Ventures Fund and Bayland Capital on May 7, 2025.
Early Stage VC
- NewLimit, developer of precision medicines designed for epigenetic reprogramming to restore youthful function in aging cells, raised $130 million of Series B venture funding in a deal led by Kleiner Perkins on May 6, 2025, putting the company’s pre-money valuation at $695 million.
- Taudia, developer of blood-based protein biomarker technology designed for neurodegenerative diseases, raised venture funding from IT-Farm in approximately May 2025.
Seed Round
- Conexeu Sciences, developer of regenerative aesthetics and wound care therapies intended to accelerate wound healing and enhance tissue regeneration, raised $1.29 million of seed funding from investors on May 8, 2025.
- MantaBio, developer of a real-time polymerase chain reaction (PCR) platform designed for automated microbial contamination detection for biopharma applications, raised $2.5 million of seed funding in the form of convertible note from investors on May 13, 2025.
#castleplacement #capitalraising #privateequity #venturecapital #investment #pharmadrugdiscovery #pharmadrugdelivery #pharmaceuticals #biotechnology
Please contact me if you have any questions or would like to discuss your capital raise:
Email: druddy@castleplacement.com
(C) (406) 868-3218
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.











